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Transport inhibitionWith the discovery of P-glycoprotein (P-gp), it became evident that ABC-transporters play a vital role in bioavail-
ability and toxicity of drugs. They prevent intracellular accumulation of toxic compounds, which renders them a
major defensemechanism against xenotoxic compounds. Their expression in cells of all major barriers (intestine,
blood–brain barrier, blood–placenta barrier) as well as in metabolic organs (liver, kidney) also explains their
inﬂuence on the ADMET properties of drugs and drug candidates. Thus, in silico models for the prediction of
the probability of a compound to interact with P-gp or analogous transporters are of high value in the early
phase of the drug discovery process. Within this review, we highlight recent developments in the area, with a
special focus on the molecular basis of drug–transporter interaction. In addition, with the recent availability of
X-ray structures of several ABC-transporters, also structure-based design methods have been applied and will
be addressed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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ATP-binding cassette transporters (ABC-transporters) form a large
superfamily of membrane proteins. Members of the ABC-transportersviews theme issue on “In silico
r).
. This is an open access article undercan be found in all living organisms from prokaryotes to mammals.
Generally speaking, these transporters participate in active transport,
i.e. they hydrolyze ATP and use its energy to transport their substrates.
In humans, 49 ABC-transporters are recognized to date and belong
to 7 distinct subfamilies [1], ABCA to ABCG. The usual “transport unit”
consists of two intracellular nucleotide binding domains and two
transmembrane domains. The nucleotide binding domains (NBDs),
usually well conserved across subfamilies, bind and hydrolyze ATP.
The transmembrane domains create the translocation chamber acrossthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and are responsible for the substrate speciﬁcity of the different trans-
porters. Members of the ABCBA subfamily transport cholesterol and
lipids [2]. Members of the B, C and G subfamilies are multi-drug
resistance-associated transporters or associated with diseases.
It was in 1976 when Juliano and Ling [3] linked the phenomenon of
anticancer multiple drug resistance to a single glycoprotein expressed
in themembranes of Chinese hamster ovary cells. Asmultiple drug resis-
tance was characterized by a decreased accumulation of the anticancer
agents in the tumor cells, they named the protein P-glycoprotein (P for
permeability). Soon after, it became evident that P-glycoprotein (P-gp)
functions as an ATP-driven, transmembrane efﬂux pump with an
extremely broad substrate speciﬁcity (polyspeciﬁcity or promiscuity).
Obviously, there were immediate attempts to develop compounds
which would block the P-gp mediated efﬂux of anticancer drugs and
thus resensitize multidrug resistant tumor cells. The ﬁrst representative
of this new class of so-called modulators of multidrug resistance
(MDR-modulators) was the calcium channel blocker verapamil [4,5].
As for substrates, also in case of inhibitors P-gp is characterized by an
extremely broad ligand proﬁle. Thus, there are currently more than
5000 compounds retrieved when you search the Open PHACTS Discov-
ery Platform [6] for compounds interacting with P-glycoprotein. Several
compounds were subject to clinical studies, but none was approved so
far. This raised the question of the druggability of P-gp, and the research
focus shifted towards its potential role as antitarget [7].
1.1. ABC-transporters and ADMET
With the increasing knowledge on the tissue expression and
function of P-glycoprotein, its important role in absorption of drugs
and drug candidates became evident. This is now broadly accepted
and has been also picked up by regulatory authorities. Based on a p-
roposal from the International Transporter Consortium, the FDA now
recommends a standardized set of experiments to assess the likelihood
of a compound to interact with P-glycoprotein and the Breast Cancer
Resistance Protein (BCRP/ABCG2) [8], another member of this super-
family of ABC-transporters. According to the multiple roles of P-gp
and analogs, both substrate and inhibitor properties of compounds
need to be explored. The latter especially is important for drug–drug in-
teractions. There are numerous cases reportedwhere co-administration
of a P-gp inhibitor with a P-gp substrate considerably increased the
blood levels of the latter, leading to serious side effects. Classical exam-
ples are drug–drug interactions with digoxin (dronedarone, quinidine,
ranolazine), loperamide (tipranavir, ritonavir), saquinavir (tipranavir,
ritonavir) for P-gp and interactions with topotecan (GF120918) for
BCRP.
Compounds inducing expression of P-gp will lead to analogous
results. However, as clearly exempliﬁed in the Biopharmaceutics Classi-
ﬁcation System (BCS) [9], the solubility of the compounds plays also an
indispensable role for assessing theﬁnal risk for transporter-related low
bioavailability. As P-gp is an ATP-driven transporter, its transport capac-
ity has limits and it can be saturated. P-gp does not play any role in the
bioavailability of highly soluble compounds, irrespective of whether
they are substrates or not. P-gp becomes the limiting step only for
substrates with low solubility. This of course increases the complexity
and renders the task of predicting bioavailability of a compound by
in silicomodels quite a challenge.
The blood–brain barrier (BBB) has been recognized as a tissue/barrier
where P-gp and BCRP play a major role in controlling the transcellular
ﬂux of small molecules. The BBB is characterized by tight junctions,
which force all solutes to take the transcellular route. Both P-gp and
BCRP are highly expressed at the BBB and thus are the major functional
constituents of this barrier. This has implications for the development
of CNS-active drugs, as these need to cross the BBB, and thus should be
devoid of P-gp and BCRP substrate properties. Especially for the therapy
of brain tumours, this is ofmajor relevance, asmost anticancer agents aresubstrates of P-gp and BCRP [10,11]. Very recent examples are provided
by the group of Schinkel, who demonstrate that brain accumulation of
the PARP inhibitor rucaparib and the JAK1/2 inhibitor CYT387 in mice
is restricted by Abcg2 and Abcb1a/1b [12,13]. In contrast, for compounds
supposed not to interact with CNS-targets, favoring P-gp substrate prop-
erties would be a versatile approach for preventing them from entering
the brain. A classical example in this respect is the class of antihistaminic
agents: the ﬁrst generation of compounds (e.g. diphenhydramine)
showed remarkable CNS-related side effects, such as dizziness, whereas
the 3rd generation of drugs, such as fexofenadine, is devoid of CNS side
effects due to their P-gp substrate properties [14]. In addition, as already
outlined previously, drug–drug interactions mediated by P-gp and BCRP
are an important issue also at the BBB [15].
1.2. ABC-transporters and liver toxicity
Canalicular ABC-transporters, which mediate the excretion of indi-
vidual bile constituents, play a key role in bile formation and cholestasis.
Some of these constituents, such as bile acids, cause serious damage to
hepatocytes and bile duct cells, which might lead to inﬂammation,
ﬁbrosis, cirrhosis, sitosterolemia, hyperbilirubinemia, cholestasis, and
potentially also cancer [16,17]. Especially, the proper interplay (see
Fig. 1) of the bile salt export pump (BSEP, gene ABCB11) with MDR3
(gene ABCB4) is critical for the formation of bile salt micelles, and inhi-
bition of BSEP has been clearly linked to drug-induced liver injury (DILI)
[18]. However, besides BSEP and MDR3, MRP2 (gene ABCC2) as well as
P-gp and BCRP are involved. Thus, there are multiple possibilities for
drugs and nutrients to interfere with the liver transportome, and we
are just beginning to understand how this is linked to hepatotoxicity.
One possible starting point are diseases linked to ABC-transporter
mutations. For example, homozygous-null MDR3 mutations cause
progressive familial intrahepatic cholestasis [19]. MDR3 ﬂops phospha-
tidylcholine into the bile canaliculus to protect the biliary tree from the
detergent activity of bile salts. Thus, a misbalance of BSEP and MDR3
activity leads to toxic concentrations of bile salts either in the hepatocyte
or in the bile duct.
1.3. Diseases related to malfunction of ABC-transporters
On a more general level, there are numerous diseases which have
been linked to improper functioning ABC-transporters. The paradigm ex-
ample is cysticﬁbrosis, which is caused bymutations of the CFTR chloride
channel [20]. The CFTR chloride channel is encoded by the ABCC7 gene,
which is mutated in patients with cystic ﬁbrosis. ATP-driven conforma-
tional changes open and close a gate to allow transmembrane ﬂow of
chloride anions down their electrochemical gradient. Very recently,
Vertex launched a drug which potentiates the function of deltaF508
mutated CFTR and thus compensates for the impaired function. Another
compound developed by Vertex acts as pharmacochaperone, thus
increasing the concentration of CFTR in the membrane.
Other examples are the link of MRP2 to Dubin–Johnson syndrome
[21], of ABCA1 to Tangier disease [22], and of BCRP to gout [23].
Finally, there is increasing evidence that P-gp, BCRP, MRP1 (gene
ABCC1) and the cholesterol transporter ABCA1 may contribute to
the pathogenesis of Alzheimer's Disease (for a review see [24]). Thus,
modulation of their activity might be a new concept for the treatment
of Alzheimer.
1.4. Drug–drug and drug–nutrient interactions
In an aging society, drug–drug interactions become an extremely im-
portant issue. Elderly patients are quite often subject to complexmedica-
tions, and the risk of severe drug–drug interactions increases with the
number of drugs. Most often, these interactions are linked to cytochrome
P450-related metabolism of compounds, i.e. compound A blocks the me-
tabolism of compound B,which increases the concentration of compound
Fig. 1.Cooperation of BSEP, ABCB4 andMRP2 in the canalicularmembrane of hepatocytes. BSEP (blue) exports the bile salts, ABCB4 (green) ﬂips phosphatidylcholine to the outer leaﬂet of
themembrane, where it is recruited by bile salts to formmixedmicelles. MRP2 (red)maintains the asymmetry in lipid composition by ﬂipping aminophospholipids to the inner leaﬂet of
the membrane.
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literature pointing towards drug–transporter interaction as additional
contributor to severe drug–drug interactions. It could be that compound
A blocks a transporter which is transporting compound B, thus inﬂuenc-
ing the distribution of compound B. Another scenario is that compound
A induces the expression of a certain transporter, which then inﬂuences
the distribution of all substrates of this transporter. A selected example
is the interaction of rifampin with the P-gp substrate digoxin, where
patients treated with rifampin and digoxin show considerably increased
digoxin levels. As the renal clearance and half-life of digoxin was not al-
tered by rifampin, this ismost probably due to an increase of the intestinal
P-gp content due to an induction of P-gp expression [25].
Another well documented example is the inﬂuence of P-gp inhibi-
tors on thedistribution ofHIV-1 protease inhibitors into brain and testes
[26]. However, a very recent study based on a detailed analysis of clini-
cal drug–drug interaction studies revealed that the risk for drug–drug
interactions caused by P-gp inhibition is quite limited. A signiﬁcant
risk could only be detected when both P-gp and CYP3A are inhibited
[27].
One of the major functions of ABC-transporters is the transport of
natural toxins. Therefore, they are deﬁnitely also linked to drug–nutrient
interactions. One prominent example are ﬂavonoids, which have been
shown in numerous studies to interact with P-gp [28–30] and BCRP
[31]. Of course, induction of protein expression — like it has been
shown for St. Johns wort (Hypericum perforatum) — and cytochromes
might also be a major issue, especially when considering that nuclear
receptors are involved for both cytochromes and ABC-transporters [32].
Considering the multiple involvement of ABC-transporters in
ADMET properties of drugs as well as their potential role as targets for
treatment of multidrug resistant tumours, it is evident that numerous
computational studies have been performedwith the aim to predict po-
tential compound–transporter interaction and to explore the molecular
basis of the polyspeciﬁcity of these transporters. These started with
ligand-based approaches, which extended to structure-based studies
when the ﬁrst X-ray structures became available.
2. Ligand-based models
2.1. Machine learning approaches for predicting inhibitors of
ABC-transporters
P-glycoprotein is deﬁnitely the paradigm protein for the whole family
of ABC-transporters. Thus, basically allmethods available for ligand-based
design have been applied. These include conventional Hansch analysis,linear andnon-linear classiﬁcation algorithms, pharmacophoremodeling,
as well as supervised and unsupervised artiﬁcial neural networks. There
are numerous reviews published which summarize these studies, and
the reader is referred to a small selection for further reading [33–38].
However, the challenges in the ﬁeld of ABC-transporter modeling are
manifold, and the main question — what is the molecular basis for the
polyspeciﬁcity — is still not solved. A large number of chemical scaffolds
for inhibitors of P-gp have been published, and, for basically all of them,
structure–activity relationships could be derived. This indicates that
there are local effects (binding sites?) which translate to a distinct
structure–activity relationship (SAR). For each scaffold investigated,
clear determinants for high and low inhibitory activity could be
established. They most often relate to quite basic physicochemical
parameters, such as lipophilicity, H-bonding, aromatic rings, and
may be also charge. However, after more than 30 years of intense
research, there is still no clear understanding of the molecular basis of
compound–transporter interactionwhichwould translate to a set of gen-
eral rules for medicinal chemists that could help them to enhance or to
avoid P-gp inhibitor properties in a lead optimization program. Interest-
ingly, also the concepts of ligand efﬁciency and lipophilic efﬁciency have
to be applied in a different way than for conventional targets [39]. In
recent years, the focus shifted to classiﬁcation models for large data sets
in order to allow in silico proﬁling of compound libraries. Also in this
area a number of publications appeared in the literature, and we will
just summarize a few recent ones to outline themain strategies followed.
One of the groundbreaking contributions is the work of Broccatelli and
colleagues [40], who used a combination of molecular ﬁeld analysis,
pharmacophore-based representation of the compounds, as well as
physicochemical descriptors to develop both global and local models for
P-gp inhibitors. Based on a data set of 1275 compounds derived from 61
references, the authors established a workﬂow which combines speciﬁc
(pharmacophore) and nonspeciﬁc (general physicochemical) descriptors
(Fig. 2). The ﬁnal model points towards ﬂexibility, hydrophobic surface
area, and logP as main discriminating physicochemical parameters for
inhibitors/non-inhibitors. Furthermore, shape also emerged as a crucial
factor, indicating the importance of the 3D description of the molecules.
The authors reported an accuracy of 0.86, speciﬁcity of 0.8, sensitivity of
0.9 and Cohen's kappa of 0.7 on a true external set.
Chen and colleagues compiled a large data set from literature, com-
prising in total 1273 compounds [41]. Their classiﬁcation approach is
based on recursive partitioning and naive Bayes categorization using a
set of physicochemical descriptors and various ﬁngerprints. Also in
their models, logP is an important contributor to distinguish inhibitors
from non-inhibitors. The introduction of ﬁngerprints remarkably
Fig. 2. Flow chart of the Composite Model. Reprinted with permission from [40]. Copyright 2011 American Chemical Society.
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0.69 and speciﬁcity of 0.70 with only physicochemical descriptors on
an external test set to a maximum of 0.84 in sensitivity and 0.87 in spec-
iﬁcity on the same set but with ﬁngerprints) and furthermore allowed to
identifymolecular fragmentswhich are favorable or unfavorable for P-gp
inhibition. However, one should bear in mind that all methods linking
substructures/fragments to biological activity of course heavily depend
on the presence/absence of these fragments in the data set. For example,
a data set which includes a series of propafenone analogs will of course
point towards the importance of an aryloxypropanolamine moiety for
P-gp inhibitory potency. However, detailed structure–activity relation-
ship studies showed that the hydroxy-group of the propanolamine
seems not to be involved in compound–transporter interaction [42].
While in the case of P-gp datasets of considerable size are available
in the literature, for most of the other ABC-transporters there is still a
lack of data for establishing in silico models. Thus, for MDR3, which is
a phospholipid transporter expressed in the liver, only 5 compounds
are retrieved by the Open PHACTS Discovery Platform [6], including
taxol, vinblastine and verapamil. Considering the fact that MDR3 is the
closest homolog to P-glycoprotein (sequence identity 75%), it seemsquite unlikely that the protein is inhibited only by ﬁve compounds. In
case of BCRP, BSEP, MRP1, and MRP2, considerable progress has been
made within the past few years, allowing developing in silicomodels.
Very recently, the hitherto largest data set for BCRP has been com-
piled by Montanari and Ecker, and includes 978 unique compounds
extracted from 47 studies [43]. Subsequently, the data set was used to
derive a Bayesian classiﬁcation model using ECFP_6 ﬁngerprints. This
allowed extracting important substructures, which are mostly in line
with currently published SAR studies around BCRP inhibition. Basically,
the number of nitrogen atoms, the aromaticity and the presence of
fused aromatic heterocycles seem to favor inhibition, while the presence
of sulfur atom, ﬁve-membered rings, or amide linkers seems to favor
inactivity. The authors report an accuracy of 0.92 and an area under the
ROC curve of 0.85 in cross-validation for this naive Bayes model.
In case of the human bile salt export pump (BSEP),Warner et al. [44]
used a recently described in vitro membrane vesicle BSEP inhibition
assay to quantify transporter inhibition for a set of 624 compounds.
Relating a set of physicochemical properties of the compounds to BSEP
inhibition, they showed that lipophilicity and molecular size are signif-
icantly correlatedwith BSEP inhibition. BSEP inhibitor classiﬁcation by a
21F. Montanari, G.F. Ecker / Advanced Drug Delivery Reviews 86 (2015) 17–26support vector machine model leads to a total accuracy of 0.87. The
model could be further used to minimize the propensity of drug candi-
dates to inhibit BSEP.
In case ofMRP2, an ABC-transporter which alsomight be involved in
drug–drug interactions in the liver, Pedersen et al. [45]measured a set of
191 structurally diverse drugs and drug-like compounds for inhibition
of MRP2-mediated transport of estradiol-17-D-glucuronide (E17G) in
inside-out membrane vesicles from Sf9 cells overexpressing human
MRP2. Based on these data, a multivariate orthogonal partial least
squares discriminant analysis (OPLS-DA) model that distinguishes
between MRP2 inhibitors and non-inhibitors was built. The model
was capable of correctly classifying 72% of the inhibitors and 71% of
the non-inhibitors in the test set. The coefﬁcients in the ﬁnal model
show that a combination of increased lipophilicity, aromaticity, and
size is a major determinant for theMRP2 inhibitory effect. Interestingly,
the authors also performed an analysis to examine whether inhibitors
that have also been reported to be substrates, and which are thus likely
to compete with E17G binding at the transport site, were structurally
different from other inhibitors. They were indeed on average less
lipophilic than other inhibitors and also had a higher molecular weight
and a larger polar surface area.
Interestingly, there are also early attempts to perform selectivity
proﬁling studies over several ABC-transporters. For example, Matsson
and colleagues [55] used a set of 122 structurally diverse drugs to
study the inhibition patterns of P-gp, BCRP, and MRP2. The inhibitor
speciﬁcities of P-gp, BCRP and MRP2 were shown to be highly overlap-
ping, and a computational model based on multivariate statistics
correctly classiﬁed 80% of general ABC transporter inhibitors and non-
inhibitors in an external test set.
2.2. Pharmacophore models for ABC-transporter inhibitors
Of course, in addition to classical QSAR of local compound series and
inhibitor/non-inhibitor classiﬁcationmodels, numerous pharmacophore
models have been derived. This is driven by the aim to understand
pharmacophoric and pharmacophobic features which determine
ligand–transporter interactions. However, due to the high structural
diversity of the ligands, also pharmacophore modeling so far did not
lead to a better molecular understanding of the molecular basis of
polyspeciﬁcity. However, most of the pharmacophore models derived
show good capabilities in identifying new ligands with new chemical
scaffolds, thus proving their utility. Brieﬂy, Palmeira et al. [46] created a
pharmacophore model based on 26 known P-gp inhibitors from the
ﬂavonoid family, which was then used to screen DrugBank. 167 struc-
tures were found to comply with the pharmacophore model with an
RMSD of b1 Å. Out of these 167 structures, 91 fulﬁlled the Lipinski
rules of 5. Finally, 21 compounds were selected for biological testing,
whereby 12 were found to signiﬁcantly increase the intracellular accu-
mulation of Rhodamine-123, a P-gp substrate. Analogously, Pan et al.
[47] created a pharmacophore model based on 25 BCRP inhibitors and
screened the Collaborative Drug Discovery Database, which comprises
2815 FDA-approved drugs selected from all medications on the market
since 1938. 33 drugs were tested in vitro for their inhibitory effects on
BCRP-mediated transport of [3H]-mitoxantrone in MCF-7/AdrVp cells,
and 19 compounds were identiﬁed with signiﬁcant inhibitory effect on
BCRP transport function. For BSEP, a small set of 5 compounds served
as basis for a pharmacophore model, which was validated against a set
of 59 compounds, including registered drugs. The model recognized 9
out of 12 inhibitors, which could not be identiﬁed based on general
parameters (such as molecular weight or SlogP) alone. Finally, the
model was used to screen a virtual compound database of commercially
available compounds. A number of compounds found via virtual screen-
ing were tested and displayed statistically signiﬁcant BSEP inhibition,
ranging from 13 ± 1% to 67 ± 7% of control (P b 0.05) [48].
A pharmacophore for MRP1 was recently built on ﬁve diverse and
potent inhibitors [36]. It is composed of 3 aromatic rings and 3 H-bonddonor features and was able to retrieve 3 known inhibitors of MRP1
among a large database of 500 drugs. For MRP2, Zhang and colleagues
[49] reported a pharmacophore built on nine potent and diverse inhibi-
tors. It contains two H-bond acceptor features and one hydrophobic
feature. The model gave a sensitivity of 78% and a speciﬁcity of 70%,
with an overall accuracy of 74%.2.3. Models for predicting substrates
While for inhibitors a set of assays is available which leads to precise
IC50 values, the case of substrates is much more complicated. Most
commonly a polarized transport assay across a monolayer of cells
overexpressing a distinct transporter is used. Thus, the in silicomodels
derived on basis of these data mostly use binary classiﬁcation
algorithms (substrate versus non substrate). To our knowledge the
largest data set for P-gp substrates/non-substrates in the public domain
was compiled by Li et al. [50] (423 substrates, 300 non-substrates).
Analyzing the distributions of eight basic physicochemical properties
for the substrates and non-substrates showed that molecular weight
and solubility are the main factors differentiating P-gp substrates from
non-substrates. When comparing the 423 substrates with a set of 735
P-gp inhibitors, inhibitors proved to be signiﬁcantly more hydrophobic
than substrates while substrates tend to have more H-bond donors
than inhibitors. Applying a naive Bayes classiﬁer using a set of simple
molecular properties, topological descriptors, and molecular ﬁnger-
prints, a classiﬁcationmodel with very good performancewas retrieved
(Matthews correlation coefﬁcient (MCC) = 0.824, prediction
accuracy = 91.2% for leave 20% out cross-validation, prediction accura-
cy of 83.5% for a test set of 200molecules). Themost important structur-
al fragments provided by the Bayesian classiﬁer indicate that H-bond
acceptors arranged in distinct spatial patterns as well as ﬂexibility are
quite essential for P-gp substrate-likeness.
In another setting, Wang et al. [51] used a set of 332 compounds to
develop a classiﬁcation model using support vector machine. The best
model (MCC = 0.73) shows a prediction accuracy of 0.88 on a test set.
Examination of the model based on ECFP_4 ﬁngerprints revealed sub-
structures such as nitrile and sulfoxide, which have a higher frequency
in non-substrates than in substrates. However, as already previously
stated, this should be taken with caution, as substructure analysis
depends on the occurrence of the respective fragments in the training
set. Also for BCRP, a larger set of 263 substrates and non-substrates
has been collated from literature and classiﬁed via a support vector
machine [52]. The ﬁnal SVM model had an overall prediction accuracy
of 73% for an independent test set of 40 compounds and was integrated
to a free web server (http://bcrp.althotas.com).
While ﬁnding a large dataset for MRP2 substrates and non-
substrates is not an easy task to date, Pinto and colleagues [53] made
use of a fuzzy dataset correlating transporter expression in cancer cell
lines with the substrate capability of the tested compounds [54] to
build classiﬁcation models predicting MRP2 substrates. The authors
reached a sensitivity of 0.77 and speciﬁcity of 0.72 in their best settings
where 16 physicochemical descriptors were used to build a cost sensi-
tive Random Forest. This technique allowed taking into account the im-
balance of the data by penalizing predictions errors made by the model
on the minority class.
In summary, there are numerousmodels publishedwhich are able to
predict inhibitors and/or substrates of the most important ABC-
transporters. All the models described here are summarized in Table 1.
However, a set of general rules with respect to the main driving factors
for ligand–transporter interaction, which go beyond lipophilicity, size,
and H-bonding, is still missing. Furthermore, most of the models lack
proper applicability domain assessment, which renders it difﬁcult to
judge their performance in a broader chemical space. Finally, when
checking the original publications where the data were coming from,
it becomes evident that numerous different assays are used to measure
22 F. Montanari, G.F. Ecker / Advanced Drug Delivery Reviews 86 (2015) 17–26ABC-transporter inhibition. Thus, an upfront careful curation of the data
seems mandatory before using them for large scale models.
3. Data curation
Working with large datasets seems to be the way to build high
quality models and derive general trends for compounds interacting
with ABC-transporters. Data, however, is scarce, at least for some
less studied transporters. Typical medicinal chemistry studies report
bioactivities for a small set of chemically related compounds. Scientists
wanting to build large datasets must collect and merge together such
data, using databases like ChEMBL [56] and Pubchem [57], but also
manual search through MEDLINE. Now, what if the groups measuring
ABC-transporters substrate or inhibition activities each use their own
assay design? Then merging together data becomes a challenging task.
Zdrazil et al. [58], studied all bioassays from ChEMBL for P-gp inhibition
and transport, when these assays reported IC50, EC50 or Ki values.
Subsequently, they annotated assays according to their potential for
being combined together in a large QSAR dataset. The results show
the importance of overlapping binding sites for the different substrates
used in the bioassays, as well as the cell line in which the transporter is
expressed.
In another recent study [59], the authors compared IC50 values
obtained across several laboratories for P-gp inhibition, each using
several assay methodologies. The variability range was over 20 fold for
all compounds tested, and the study concluded that themost important
actor was inter-laboratory variability rather than inter-assay variability.
Beyond the assay diversity and inter-laboratory variabilities, Balimane
and colleagues [60] have pointed out yet another source of variability,
namely the calculation of inhibition given one raw set of data measured
on one assay by one laboratory. It seems that, depending on the calcula-
tionmethod used, one can draw entirely different conclusions regarding
the inhibition capability of compounds.
For other less studied transporters like BCRP, the picture gets worse:
most of the assays use different cell lines, and little is known about the
binding sites of the different substrates used in these assays [61]. The
resulting problem is that a compound may show activity in an assay
with a given substrate, but no activity in the presence of another
substrate. One solution is to compare activities reported across distinct
assays, exclusively use the data for building classiﬁcation models,
apply a threshold for activity assay by assay and remove problematic
compounds [43].Table 1
Summary of all ligand-based models described in Section 2.
Transporter Type of model Dataseta
P-gp Combined 1275 inhibitors
P-gp Naive Bayes 1273 inhibitors
P-gp Pharmacophore 26 inhibitors
P-gp Naive Bayes 723 substrates
P-gp SVMb 332 substrates
BCRP Naive Bayes 978 inhibitors
BCRP Pharmacophore 25 inhibitors
BCRP SVMb 263 substrates
BSEP SVMb 624 inhibitors
BSEP Pharmacophore 5 inhibitors
MRP2 OPLS-DAc 191 inhibitors
MRP2 Pharmacophore 9 inhibitors
MRP2 Random Forest 1204 substrates
MRP1 Pharmacophore 5 inhibitors
P-gp, BCRP, MRP2 PLS-DAd 122 inhibitors
a Size and type of data (for models that are not pharmacophores, both active and inactive a
b Support vector machine.
c Orthogonal partial least squares discriminant analysis.
d Partial least squares discriminant analysis.To alleviate the aforementioned problems related with bioactivity
data in the ﬁeld of transporters, one could propose some simple mea-
sures to apply and change the current habits in the ﬁeld.While agreeing
on a speciﬁc assaymethodology seems a bit irrealistic, a set of reference
compounds for each transporter could be deﬁned (both inactives
and actives) and recommend that each laboratory willing to publish
new bioactivity data must also report the bioactivities obtained on
their assay for this group of reference compounds. That way, inter-
laboratory and inter-assay differences would be immediately spotted
and taken care of appropriately when merging data from different
sources.
4. Structure-based models
Due to the tremendous progress in the ﬁeld of structural biology,
structures of transmembrane transporters, including several ABC-
transporters, became available. Most of them were from prokaryotes,
and only very recently structures from eukaryotic organisms were
also resolved in a resolution which allows starting structure-based
approaches. However, the only human ABC-transporter crystallized so
far is ABCB10 [62]. Nevertheless, the whole ﬁeld of ABC-transporter
research was inspired by the ﬁrst structures being deposited in the Pro-
tein Data Bank [63], and protein homology models of P-gp immediately
became available.
More recent templates available for homologymodeling are provided
in Table 2.
Although most of these structures are in sufﬁcient resolution to
serve as templates for structure-based studies, one needs to bear in
mind that there is still noprotein structure cocrystallizedwith a classical
substrate/inhibitor, such as verapamil or cyclosporin. The only structure
which includes a small molecule is the one from mouse P-gp [65].
Furthermore, the transporters undergo a substantial conformational
change when progressing through the transport cycle, which renders
all structures available only snapshots of a very distinct point in the
whole conformational space. Nevertheless, especially for P-gp, numer-
ous docking studies of selected ligands into homology models were
performed with the aim to understand the molecular determinants of
binding (for reviews, see e.g. [33,34,35,72,37]). However, experimental
validation, especially with respect to prospective validation of the bind-
ing hypotheses retrieved, is mostly missing. In this section we will thus
focus on recent advances where structure-based studies were used
more in the sense of virtual screening rather than providing distinctPredictivity Publication
Accuracy: 0.86 Broccatelli et al. [40]
Sensitivity: 0.835
Speciﬁcity: 0.866
Chen et al. [41]
12/21 tested were active Palmeira et al. [46]
Accuracy: 0.84 Li et al. [50]
Accuracy: 0.88 Wang et al. [51]
Accuracy: 0.92 Montanari and Ecker [43]
19/33 tested were active Pan et al. [47]
Accuracy: 0.73 Hazai et al. [52]
Accuracy: 0.87 Warner et al. [44]
Sensitivity: 0.75 Ritschel et al. [48]
Sensitivity: 0.72
Speciﬁcity: 0.71
Pedersen et al. [45]
Accuracy: 0.74 Zhang et al. [49]
Sensitivity: 0.77
Speciﬁcity: 0.72
Pinto et al. [53]
Not clear Chang et al. [36]
Accuracy: 0.8 Matsson et al. [55]
re present).
Table 2
Existing 3D structures of ABC transporters in the Protein Data Bank (PDB).
Year Publication PDB IDs Species Protein Res.a State
2012 Jin et al. [64] 4F4C C. elegans Pgp-1 (Uniprot: P34712) 3.4 Å Open-in
2012 Shintre et al. [62] 3ZDQ,
4AYT, 4AYX, 4AYW
H. sapiens ABC transporter 10 protein (Uniprot: Q9NRK6) 2.85 Å Open-in
2009 Aller et al. [65] 3G5U
3G60
3G61
M. musculus MDR1A (Uniprot: P21447) 3.8 Å Open-in




M. musculus MDR1A (Uniprot: P21447) 3.8 Å Open-in
2014 Li et al. [67] 4M1M,
4M2S,
4M2T
M. musculus MDR1A (Uniprot: P21447) 3.8 Å Open-in
2007 Dawson and Locher [68] 2ONJ S. aureus SAV1866 (Uniprot: Q99T13) 3.4 Å Open-out
2006 Dawson and Locher [69] 2HYD S. aureus SAV1866 (Uniprot: Q99T13) 3.0 Å Open-out
2007 Ward et al. [70] 3B5Y,
3B5Z,
3B60
S. typhimurium Permease protein msbA (Uniprot: P63359) 3.7 Å Open-out
2012 Hohl et al. [71] 3QF4 T. maritima Uncharacterized ABC transporter (Uniprot: Q9WYC4) 2.9 Å Open-in
a Resolution. When more than one PDB ID is given, the lowest resolution is reported.
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ﬂexible receptor docking protocol for docking a set of 26 drugs known
to interact with P-gp. 102 endogenous metabolites, assuming that
they will not interact with the transporter, served as negative control.
As a template, mouse P-gp bound to the cyclic peptide QZ59-RRR was
used. Subsequently, the dataset from Doan et al. [74] of FDA-approved
drugs that included results of the monolayer efﬂux and CAM inhibition
assays, was used for docking. The results suggest that many P-gp sub-
strates bind deeper in the cavity than the cyclic peptide in the crystal
structure, and that speciﬁcity in P-gp is better understood in terms of
physicochemical properties of the ligands (and the binding site), rather
than being deﬁned by speciﬁc sub-sites. Klepsch et al. [75] also built on
themouse P-gp complexedwith QZ59-RRR and implemented a docking
protocol which exhaustively samples the pose space of a small set of
ligandswhich show a distinct SAR pattern followed by common scaffold
clustering. The SAR information is then used to priorities the pose
cluster in order to retrieve an experimental-data-guided binding
hypothesis. Subsequently, the docking protocol was used to classify a
large set of 1608 inhibitors and non-inhibitors of P-gp. Although the
performance of the structure-based classiﬁcation was considerably
lower (61% for the external test set) than those obtained by Random
Forest or SVM classiﬁcation (73% and 75%, respectively), it shows
that structure-based classiﬁcation of ligands of ABC-transporter is
within reach [76]. A very comprehensive approachwas used by Ferreira
et al. [77]. Using a previously reﬁned structure of murine P-gp, they
characterized the M-, H- and R-site by means of molecular docking.
The drug-binding pockets were deﬁned as substrate- or modulator-
binding sites according to the molecules that preferentially docked in
each location. For the authors, “modulator” refers to compounds that
appear to block the efﬂux of substrates. The substrate-binding sites H
and R refer to Hoechst 33342 and rhodamine-123, respectively.
Analogously, the modulator-binding (M) site was linked to the main
interaction site for verapamil. Subsequently, they carried out further
docking studies with molecules classiﬁed as substrates or modulators
in order to retrieve a structure-based classiﬁcation model with the
ability to discriminate substrates from modulators. The classiﬁcation
scheme contains fourmain categories: (i) non-substrates, (ii) transported
substrates, (iii) non-transported substrates, and (iv) modulators (Fig. 3).
Their model properly predicted 14 modulators out of 19 (74%), 20
substrates out of 32 (63%) and 2 out of 3 non-substrates. However, the
authors rightly conclude that “.... the substrate-binding sites may present
different characteristics at different steps of the efﬂux mechanism, possibly
interconverting the H-site and the R-site in one another, partially explaining
the induced-ﬁt and polyspeciﬁcity models proposed for Pgp substraterecognition”, and point towards the importance of molecular dynamics
simulations for further insights into the dynamics of the protein.
In a different publication [78], the authors indeed performed 100 ns
molecular dynamics simulations in order to reﬁne their homology
model. Subsequent 20 ns production runs with a small set of ligands
indicated that the number of interactions established between several
ligands and the drug binding pocket might allow distinguishing inhibi-
tors from substrates. Indeed, the modulators studied consistently
established a higher number of nonbonded interactions, mainly
aromatic ones, when compared with substrates. In the particular case
of verapamil, the increased nonbonded interactions established, which
is also shown by the modulator tariquidar, classiﬁes the molecule as a
modulator. This is well in accordance with a previously developed
pharmacophore [79], where the ability to establish a greater number
of hydrophobic interactions within the pocket is one of the major
features that allows a molecule to block competitively the substrate
binding. These studies convincingly demonstrate that structure-based
modeling in the ﬁeld of ABC-transporter has become a valuable tool
for a deeper understanding of the molecular features driving ligand–
transporter interaction. However, almost all studies focus on P-gp.
This is mainly due to the fact that both mammalian structures available
are from transporters belonging to the B-family (P-gp and ABCB10). The
C-family has the so-called TMD 0, which consists of 5 transmembrane
helices (thus having 5+ 12 transmembrane helices) where no suitable
template exists. Even worse is the case of members of the G family
(BCRP), which show a reversed order of nucleotide binding domain
and transmembrane domain. Although there is a considerable substrate
and inhibitor overlap between P-gp and BCRP, there is no suitable
template for modeling the whole transporter. Thus, new structures are
heavily awaited by the community. These might well use also other
methods than X-ray crystallography, such as the one of TmrAB
published by the Tampe group in November 2014 [80].
5. Future challenges
Challenges in theﬁeld of ABC-transporter aremanifold.With respect
to the prediction of drug transporter interaction, there are on our point
of view several immediate issues which should bementioned. Themost
obvious one is the availability of an atomic resolution structure of
human P-glycoprotein in complex with a prototype ligand such as
verapamil. This would allow benchmarking all docking studies on this
structure, which deﬁnitely would increase the validity of the binding
hypotheses retrieved. Nevertheless, in early drug discovery, in silico
models based on machine learning will still be the main tools for
Fig. 3. Classiﬁcation scheme for P-gp substrates. Reprinted with permission from [78]. Copyright 2013 American Chemical Society.
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will only show high predictivity if the underlying data are of high
quality and of a considerable size. In case of P-glycoprotein, the size of
the datasets available in the public domain is sufﬁcient, but the use of
almost 50 different assays currently does not allow combining all the
data and to compile a large, high quality dataset for training themodels.
For ABC-transporters other than P-glycoprotein, the situation is even
worse, as already the available datasets are small. For solving the issue
of different assays, a transporter assay ontology combined with the
deﬁnition of a set of standard reference compounds would be highly
recommended.
Another important issue is the ﬂexibility inherent to P-gp and most
probably to all transmembrane transporters [81]. Even if therewould be
a set of crystal structures, they still would only cover a small portion of
the conformational space of the transporter. With the ever increasing
computing power, also pushed by GPU clusters, large grids and special
computer hardware,molecular dynamics simulations of transmembrane
proteins in the ms range are possible. Simulating an ABC-transporter
through the whole transport cycle and validating/constraining the
simulation by respective biophysical and biochemical experiments
seems already feasible. Once the system is established, this would also
allow including small molecules, be it substrates, inhibitors, or modula-
tors. However, also the composition of the membrane, its cholesterol
content, as well as the behavior of the ligand in the membrane needs
to be considered [82]. This opens another layer of complexity for full
atomic simulations. Another issue linked to dynamics is the on- and
off-kinetics of the ligands. There is increasing evidence that the dissocia-
tion kinetics of a given drug from its target (its residence time) may be
more relevant for the in vivo efﬁcacy than its in vitro equilibrium binding
constant. Recent examples demonstrate that receptor subtype selectivity
might be driven by differences in dissociation kinetics rather than by
afﬁnity differences [83]. We have ﬁrst evidence in our lab that this is
also the case for propafenone-type inhibitors of P-gp, and also other
groups already speculated on this [84].
The importance of ligand–transporter interaction for prediction
of toxicity and safety needs much more attention. As outlined in the
introduction, ABC-transporters play a major role in toxicity related to
drug–drug interaction. However, due to the multiple interplay of
several transporters, this requires more complex strategies. In might
well be that there are a sort of redundant backup systems, where one
transporter can compensate for the functional failure of another one.
A well established example is the interplay of P-gp and BCRP at the
blood–brain barrier. But also in the liver there are numerous ABC-
transporters, which have to be considered. There are already a few publi-
cations available which attempt to simultaneously predict the interaction
of a compound of interest with several transporters (not necessarily only
ABC-transporter; see e.g. [85]). Selectivity proﬁling, of course, is strongly
linked to the availability of proper data, as one would need a matrix of aset of compounds measured at all transporters of interest. These models
could then be further used for linking in vitro interaction proﬁles to
in vivo effects, as recently has been shown for a set of antidepressant
drugs and their side effects observed in clinical studies [86]. This would
allow including ligand–transporter interaction proﬁles into very early
safety considerations and help to reduce late stage failures in clinical
studies.
6. Conclusions
ABC-transporters represent an integral and important part of the
human transportome. Although there are only 49 genes described in
humans, they fulﬁll important roles and are strongly linked to drug
absorption, distribution, and elimination. Furthermore, besides cyto-
chromes, they are also involved in drug–drug interactions and thus
also toxicity of drugs. With the increasing accessibility of biological
data and the tremendous progress of structural biology, our under-
standing of the molecular basis of ligand–transporter interaction is
progressing. In this review, we have outlined recent ligand-based
models built on large datasets rather than on congeneric series. While
these models allow screening rapidly large databases of molecules to
predict their substrate or inhibition properties, their interpretation
remains at the level of substructures or general physico-chemical
properties. On the structure-based side, the presence of crystal struc-
tures of the B subfamily allowed building high quality homologymodels
for P-gp and a mapping of different binding sites has started. Such
advances have not yet been noted for other ABC-transporters, but we
believe that new structureswill appear in the PDB thatwill allow similar
studies to be performed.
However, the inﬂuence of on- and off-kinetics of ligands on their
efﬁcacy as well as the multiple interplay of ABC-transporters under
in vivo conditions pose additional challenges which the community
will face in the near future.
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